Immix Biopharma, Inc. (IMMX)
AI stock analysis · as of Jun 20, 2026
Loading microstructure…
Immix Biopharma (IMMX) is a clinical-stage CAR-T biotech developing NXC-201 for relapsed/refractory AL amyloidosis, an orphan disease with no FDA-approved therapies. The core investment question is whether the reported 75% complete response rate in the Phase 2 NEXICART-2 trial will hold across the full 40-patient cohort and translate into BLA approval, justifying a ~$620M market cap on zero revenue, or whether dilution, competitive entry, and clinical risk will impair the equity.
valuationExpensive on traditional metrics (5.5x P/B, negative EV/EBITDA, no revenue) but defensible as optioned binary on NXC-201 approval; consensus $19.75 target implies the Street is underwriting a high probability of BLA success at a multi-billion peak sales asset.
This analysis is from Jun 20, 2026. Want the latest on IMMX, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Best-in-class efficacy signal: 75% complete response rate (15/20) by independent review at ASH 2025 in a fatal disease with no approved therapies, with clean safety (no neurotoxicity, low-grade CRS only)
- · Regulatory tailwinds stack: FDA Breakthrough Therapy designation (Jan 2026), RMAT (Feb 2025), and Orphan Drug status in U.S./EU provide 7-10 years of post-approval exclusivity plus accelerated approval pathways
- · Balance sheet de-risked: $93.9M cash plus ~$100M December 2025 raise and reported $140-150M May 2026 raise provide runway into 2028, covering BLA filing without immediate refinancing pressure
- · Strong institutional validation: Janus Henderson disclosed a 9M+ share 13G/A position; institutions hold ~45% of float, and 7-analyst consensus is strong buy with $19.75 mean target (~127% upside)
- · Large addressable market: U.S. AL amyloidosis prevalence growing 12%/year (~38,500 patients in 2026); global amyloidosis market projected at $11B+ by 2033 with no incumbent approved competition in r/r setting
- · Insider alignment: 17.6% insider ownership is high for a clinical-stage biotech, and no insider net selling is disclosed in the data
Bear case
- · Pre-revenue with deep losses: FY2025 net loss of $29.4M (widening from $21.6M in 2024 and $15.4M in 2023); FCF of -$24.7M annually; ROE of -74% reflects ongoing cash burn
- · Dilution is structural: share count grew to ~53M by March 2026 after a 19.1M-share December offering at $5.10 and another ~$140-150M raise in May 2026 — equity is the funding model and will continue to dilute
- · Single-asset, small-trial risk: entire thesis rests on NXC-201 holding efficacy through a 40-patient trial; rare-disease enrollment is slow and any safety/efficacy slippage in the back half could collapse the BLA case
- · Competitive overhang: Abbvie, Alexion/AstraZeneca, and Janssen are developing AL amyloidosis therapies, and approved BCMA CAR-Ts from BMS and J&J could enter the indication with manufacturing scale Immix lacks
- · License obligations: ~$13M in quarterly Hadasit/BIRAD payments through Sept 2026 plus 5% royalties and up to $20M in sales milestones create meaningful cash drag
- · Manufacturing dependence: 100% reliance on third-party CMOs for cGMP supply is a recurring failure point for small CAR-T developers
- · Valuation is rich on optionality alone: P/B of 5.5x and ~$620M market cap on zero revenue prices in substantial approval probability
Catalysts
- · NEXICART-2 full 40-patient readout — pivotal data event for BLA support
- · BLA submission timing and FDA filing acceptance under Breakthrough/Accelerated Approval pathway
- · Additional Phase 2 data updates at medical conferences (ASH, ASCO)
- · Receipt of remaining ~$1.8M CIRM milestone tranches signaling clinical progress
- · Further institutional 13G/13F disclosures following recent Janus Henderson accumulation
- · Short interest at 6.85% of float with 3.15-day cover is modest but could amplify upside on positive data prints
Key risks
- · Phase 2 efficacy regression as the 40-patient cohort matures — the 75% CR rate is from only 20 patients
- · Continued equity issuance diluting existing holders before any commercial revenue arrives
- · FDA requiring a larger or randomized confirmatory trial, pushing approval and adding cash needs
- · Competitive CAR-T or non-CAR-T entrant reaching AL amyloidosis approval first
- · CMO manufacturing failure or cGMP issue halting NEXICART-2 enrollment
- · Section 382 limitations restricting NOL utility if/when revenue materializes
What to watch
- · Next quarterly 10-Q for cash burn rate and NEXICART-2 enrollment update
- · Any interim data or conference abstract releases (ASH late 2026, ASCO mid-2026)
- · BLA submission timing guidance from management
- · Short interest trend — currently 6.85% of float, watch for buildup pre-data
- · 52-week range $1.94-$11.61: $11-12 is technical resistance, $5-6 (recent offering price) is key support
- · Additional 13D/13G filings from institutional accumulators
Key metrics
Price target rationale
Base case ($12.50) assumes successful Phase 2 completion and BLA filing with ~$1.5B risk-adjusted NPV across ~70M diluted shares, applying ~60% probability of regulatory success. Bull case ($22) aligns with Street high if full 40-patient data confirms 75% CR and BLA is accepted under Accelerated Approval. Bear case ($3.50) reflects efficacy slippage, additional dilutive raises, or competitive entry forcing the stock back toward its 52-week low of $1.94 plus residual cash value.
On Wall Street's view (mixed): The $19.75 consensus mean (127% upside) is plausible if NEXICART-2 confirms 70%+ CR rates and a BLA filing proceeds, but it assumes near-perfect execution and ignores another likely dilutive raise before commercialization; a more risk-adjusted target sits well below the Street's high case.
Latest filing (10-K)
Immix Biopharma is a cash-funded clinical-stage CAR-T company with a 75% complete response rate in a fatal orphan disease with no approved treatments, FDA Breakthrough designation in hand, $100M just raised, and a BLA submission on the horizon if its 40-patient trial holds up.
Immix Biopharma (IMMX) is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, with its lead candidate NXC-201 targeting relapsed/refractory AL amyloidosis, a rare and life-threatening protein-misfolding disease with no FDA-approved treatments. The company has no product revenue and funds operations through equity issuances; it generates modest non-cash income from Australian R&D tax incentives. Its strategy is to complete the 40-patient NEXICART-2 Phase 1b/2 trial and submit a BLA for NXC-201.
What the news says · bullish
The dominant storyline for IMMX is a wave of fresh analyst coverage initiating with bullish ratings (B of A Securities, LifeSci Capital) and price targets implying 113-120% upside, coinciding with a successful ~$140-150M capital raise in late May 2026 that funds NXC-201 development into 2028. The financing removes near-term cash concerns and validates institutional interest, with Janus Henderson disclosing a 9M+ share position. However, the bullish thesis carries meaningful caveats: the Benzinga piece flags safety and adoption questions around the lead asset, the stock was trading near $9 after a ~6% decline in April, and the large equity offering likely caused dilution. Coverage is moderately broad but skews heavily toward analyst price-target pieces and insider option grants, which warrants some skepticism about the depth of fundamental validation.
This analysis is from Jun 20, 2026. Markets move. Get the current read on IMMX and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.